Work

Abstract PD17-12: Primary efficacy and safety results from the AMALEE trial evaluating 600 mg vs 400 mg starting doses of first-line ribociclib in patients with HR+/HER2− advanced breast cancer

Year: 2023

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.sabcs22-pd17-12

Authors: Fatima Cardoso, William Jacot, Sherko Küemmel, Sudeep Gupta, Rama Balaraman, Liudmila Lebedeva, Yan Ji, Aparna Lakshmanan, Khalid Amin, Zheng Li, Joseph Sparano

Institutions: Champalimaud Foundation, Inserm, Université de Montpellier, Institut de Recherche en Cancérologie de Montpellier, Kliniken Essen-Mitte, Advanced Centre for Treatment, Research and Education in Cancer, Novartis (India), Mount Sinai Health System

Language: English

Topic: Advanced Breast Cancer Therapies

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4322769252

Cites:

Cited by: 15

Related to: 10